TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31356143

Group type: EXPERIMENTAL
Intervention: TAA-Ts (Tumor-associated antigen cytotoxic T cells) infused at three dose levels: 1, 2, and 4 × 10^6 cells
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: TAA-Ts at the highest dose level
Number of subjects: 15

Group type: COMPARATOR
Intervention: Prior therapy (control)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: TAA-Ts
Number of subjects: 15
Study: 31356217

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 31356375

Group type: EXPERIMENTAL
Intervention: Neuraxial labour analgesia
Number of subjects: 599

Group type: COMPARATOR
Intervention: No neuraxial labour analgesia (Control)
Number of subjects: 599
Study: 31356470

Group type: EXPERIMENTAL
Intervention: Double-lumen 5F peripherally inserted central catheter
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Single-lumen 4F peripherally inserted central catheter
Number of subjects: 20
Study: 31356494

Group type: EXPERIMENTAL
Intervention: Retinal vascular bed area (RVBA) in eyes with DME
Number of subjects: 29

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Nonperfusion area in eyes with DME
Number of subjects: 29
Study: 31357748

Group type: EXPERIMENTAL
Intervention: nal-IRI+5-FU/LV
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: nal-IRI monotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: 5-FU/LV combination therapy
Number of subjects: 0
Study: 31357891

Group type: EXPERIMENTAL
Intervention: Patients with undiagnosed COPD
Number of subjects: 137

Group type: COMPARATOR
Intervention: Patients without COPD
Number of subjects: 137
Study: 31357993

Group type: EXPERIMENTAL
Intervention: ACP video intervention
Number of subjects: 119
Study: 31358485

Group type: EXPERIMENTAL
Intervention: Bortezomib (BTZ) administered at peak G-CSF mobilization
Number of subjects: 10

Group type: COMPARATOR
Intervention: Granulocyte colony-stimulating factor (G-CSF) administered for 5 days
Number of subjects: 10
Study: 31358508

Group type: EXPERIMENTAL
Intervention: Admission to high volume hospitals (>40 pulmonary embolisms per year)
Number of subjects: 39257

Group type: COMPARATOR
Intervention: Admission to low volume hospitals (<15 pulmonary embolisms per year)
Number of subjects: 39257
Study: 31358597

Group type: EXPERIMENTAL
Intervention: Major bleeding
Number of subjects: 40004

Group type: EXPERIMENTAL
Intervention: Myocardial injury after noncardiac surgery (MINS)
Number of subjects: 40004

Group type: EXPERIMENTAL
Intervention: Sepsis
Number of subjects: 40004
Study: 31359190

Group type: EXPERIMENTAL
Intervention: Aneurysm to brainstem ratio (ABR) in medial group
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Aneurysm to brainstem ratio (ABR) in lateral group
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Giant intracranial aneurysm volumes
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Brainstem compression ratio (BCR) in medial group
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Brainstem compression ratio (BCR) in lateral group
Number of subjects: 28
Study: 31359304

Group type: EXPERIMENTAL
Intervention: In situ embolization combined with surgical resection
Number of subjects: 9
Study: 31359361

Group type: EXPERIMENTAL
Intervention: quizartinib 20 mg/day
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: quizartinib 30 mg/day
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: quizartinib 60 mg/day
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: quizartinib
Number of subjects: 16
Study: 31359403

Group type: EXPERIMENTAL
Intervention: Caloric restriction (CR) based on resting metabolic rate (RMR) and 3-month structured exercise training (SSET)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Combined intervention with SSET and CR
Number of subjects: 23
Study: 31359498

Group type: EXPERIMENTAL
Intervention: Uphold LITE mesh
Number of subjects: 121
Study: 31359808

Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Number of subjects: 0
Study: 31359863

Group type: EXPERIMENTAL
Intervention: myBETAapp usage
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: wellness tracker usage
Number of subjects: 94
Study: 31359874

Group type: EXPERIMENTAL
Intervention: Sustained virological response (SVR) using direct-acting antiviral therapies
Number of subjects: 162
Study: 31360532

Group type: EXPERIMENTAL
Intervention: Comprehensive echocardiography protocol including transthoracic and transesophageal echocardiography.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Assessment of conventional and unconventional vascular risk factors.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Novel pathophysiological brain-heart pathways.
Number of subjects: 0
Study: 31360988

Group type: EXPERIMENTAL
Intervention: Highest quartile of phosphatidylcholine intake
Number of subjects: 2497

Group type: EXPERIMENTAL
Intervention: Total choline intake
Number of subjects: 2497

Group type: EXPERIMENTAL
Intervention: Higher intakes of total choline and phosphatidylcholine
Number of subjects: 2497
Study: 31361205

Group type: EXPERIMENTAL
Intervention: Cardiac MRI with texture analysis of T1 and T2 maps
Number of subjects: 71

Group type: COMPARATOR
Intervention: Endomyocardial biopsy (EMB)
Number of subjects: 71
Study: 31361303

Group type: EXPERIMENTAL
Intervention: Surgical therapy
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Pegvisomant therapy
Number of subjects: 23

Group type: COMPARATOR
Intervention: Active acromegaly
Number of subjects: 23
Study: 31362540

Group type: EXPERIMENTAL
Intervention: 25-mm Meridian valve
Number of subjects: 25
Study: 31362654

Group type: EXPERIMENTAL
Intervention: Autologous cell transplantation with LentiGlobin (HGB-207 trial)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Resveratrol (herbal therapeutic approach)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hematopoietic stem cell transplantation (HSCT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ActRIIB/IgG1 Fc recombinant protein
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gene correction strategies (e.g., suppression of BCL11A, HPFH, zinc-finger nucleases)
Number of subjects: 0
Study: 31363416

Group type: EXPERIMENTAL
Intervention: Usual care plus audio-recorded discharge discussion
Number of subjects: 50

Group type: COMPARATOR
Intervention: Usual care (verbal discussion and written summary)
Number of subjects: 50
Study: 31364010

Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine (PCV13), two doses 8 weeks apart
Number of subjects: 91

Group type: COMPARATOR
Intervention: 23-valent polysaccharide vaccine (PPV23), one dose
Number of subjects: 91
Study: 31364233

Group type: EXPERIMENTAL
Intervention: Flexible BI/GLP-1RA combination
Number of subjects: 609

Group type: COMPARATOR
Intervention: Fixed BI/GLP-1RA combination
Number of subjects: 609
Study: 31364451

Group type: EXPERIMENTAL
Intervention: Atrial fibrillation
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Multiple potential embolic sources (PES)
Number of subjects: 800

Group type: COMPARATOR
Intervention: No specific intervention reported
Number of subjects: 800
Study: 31364457

Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine (TCM), specifically Salvia miltiorrhiza, administered intravenously to 74.7% of patients.
Number of subjects: 10004

Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine (TCM) use in hospitals (99.4% of hospitals used TCM).
Number of subjects: 10004

Group type: EXPERIMENTAL
Intervention: Patients with coronary artery disease.
Number of subjects: 10004

Group type: EXPERIMENTAL
Intervention: Patients with stroke.
Number of subjects: 10004
Study: 31364601

Group type: EXPERIMENTAL
Intervention: YouTHrive (YT) intervention - access to the YT site for 5 months
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control group - weekly email newsletter on HIV topics excluding ART adherence for 5 months
Number of subjects: 300
Study: 31364602

Group type: EXPERIMENTAL
Intervention: Refined intervention (beta-i) for increasing small businesses' involvement with YPAOs.
Number of subjects: 10

Group type: COMPARATOR
Intervention: Standard practice intervention provided to the control group of neighborhoods.
Number of subjects: 10
Study: 31364979

Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg
Number of subjects: 1020

Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg
Number of subjects: 1020

Group type: COMPARATOR
Intervention: Etanercept 25 mg
Number of subjects: 1020
Study: 31365116

Group type: EXPERIMENTAL
Intervention: Eribulin
Number of subjects: 256
Study: 31365335

Group type: EXPERIMENTAL
Intervention: CT-P13
Number of subjects: 244
Study: 31366074

Group type: EXPERIMENTAL
Intervention: Catestatin (CST) levels in ADHF patients with MI history
Number of subjects: 90
Study: 31366330

Group type: EXPERIMENTAL
Intervention: Opioid-free anaesthesia (OFA) with lidocaine, dexamethasone, and ketamine
Number of subjects: 110

Group type: COMPARATOR
Intervention: Opioid anaesthesia (OA) with sufentanil
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Opioid-free anaesthesia (OFA)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Opioid anaesthesia (OA)
Number of subjects: 110
Study: 31366659

Group type: EXPERIMENTAL
Intervention: PreLiFe programme
Number of subjects: 460

Group type: COMPARATOR
Intervention: Attention control group
Number of subjects: 460
Study: 31367455

Group type: EXPERIMENTAL
Intervention: Living kidney donation
Number of subjects: 1042
Study: 31367462

Group type: EXPERIMENTAL
Intervention: Dyadic yoga (DY) intervention
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Caregiver yoga (CY) intervention
Number of subjects: 75

Group type: COMPARATOR
Intervention: Wait-list control (WLC) group
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: All groups (DY, CY, WLC)
Number of subjects: 75
Study: 31367468

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept injection (IAI) 2 mg every 4 weeks until no evidence of fluid, then 2 mg every 8 weeks
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept injection (IAI)
Number of subjects: 20
Study: 31367511

Group type: EXPERIMENTAL
Intervention: Before-school physical activity program (BOKS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 31367538

Group type: EXPERIMENTAL
Intervention: Pemetrexed 500 mg/m² and sirolimus (oral daily after loading dose)
Number of subjects: 42
Study: 31367691

Group type: EXPERIMENTAL
Intervention: Hypocaloric diet with 1 Hass avocado daily
Number of subjects: 51

Group type: COMPARATOR
Intervention: Hypocaloric diet without Hass avocado
Number of subjects: 51
Study: 31367759

Group type: EXPERIMENTAL
Intervention: Energy expenditure predictions
Number of subjects: 0
Study: 31368034

Group type: EXPERIMENTAL
Intervention: Taselisib (2-6 mg tablet or 3-6 mg capsule) plus docetaxel
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Taselisib (2-6 mg tablet or 3-6 mg capsule) plus paclitaxel
Number of subjects: 80
Study: 31368401

Group type: EXPERIMENTAL
Intervention: Disease-modifying therapies (DMTs)
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: External locus of control (influential others such as physicians)
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: Non-active disease status
Number of subjects: 377
Study: 31368441

Group type: EXPERIMENTAL
Intervention: Exergaming (EXG)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Treadmill exercise (TE)
Number of subjects: 22
Study: 31368720

Group type: EXPERIMENTAL
Intervention: Inpatient treatment for eating disorders with a focus on trauma work, fostering patient agency, and relational dynamics in patient-therapist dyad.
Number of subjects: 11
Study: 31368718

Group type: EXPERIMENTAL
Intervention: Higher BMI
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Former/current smoking status
Number of subjects: 100

Group type: COMPARATOR
Intervention: Former vs. current smokers
Number of subjects: 100

Group type: COMPARATOR
Intervention: Global sleep quality, sleep latency, and sleep efficiency
Number of subjects: 100
Study: 31368742

Group type: EXPERIMENTAL
Intervention: Lifetime history of TBI
Number of subjects: 1060

Group type: EXPERIMENTAL
Intervention: Recent deployment-related mild TBIs
Number of subjects: 1060
Study: 31368837

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 31369089

Group type: EXPERIMENTAL
Intervention: rhPTH(1-84) 25 or 50 µg/d initially, with 25-µg adjustments permitted to a 100 µg/d maximum
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: rhPTH(1-84)
Number of subjects: 49
Study: 31369102

Group type: EXPERIMENTAL
Intervention: Potassium-depleted diet
Number of subjects: 12

Group type: COMPARATOR
Intervention: Tetracosactide test in GS patients
Number of subjects: 12
Study: 31369217

Group type: EXPERIMENTAL
Intervention: Dancing people versus dynamic geometrical images
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Biological motion (dynamic light point walking human or cat) versus nonbiological motion (scrambled controls)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Child playing with toy versus toy alone
Number of subjects: 69
Study: 31369400

Group type: EXPERIMENTAL
Intervention: Recommended weight gain (n=8, 15%) during the second and third trimesters
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Excess weight gain (67%)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Recommended energy balance
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Excess energy balance
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Inadequate energy balance
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Energy intake requirements for recommended weight gain during the second and third trimesters
Number of subjects: 54
Study: 31369558

Group type: EXPERIMENTAL
Intervention: Single Kato-Katz (reference method)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: qPCR
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mini-FLOTAC
Number of subjects: 0

Group type: COMPARATOR
Intervention: FECPAKG2
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single Kato-Katz
Number of subjects: 0
Study: 31369562

Group type: EXPERIMENTAL
Intervention: Albendazole (ALB)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Kato-Katz (single and duplicate)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mini-FLOTAC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FECPAKG2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: qPCR
Number of subjects: 0
Study: 31369720

Group type: EXPERIMENTAL
Intervention: Lower peak and accelerated decline in FEV
Number of subjects: 3171
Study: 31369873

Group type: EXPERIMENTAL
Intervention: Additional ATP sequences (>3 in VT zone or >1 in FVT zone)
Number of subjects: 4112

Group type: COMPARATOR
Intervention: Nominal group (≤3 ATP sequences in VT zone or ≤1 ATP sequence in FVT zone)
Number of subjects: 4112
Study: 31370698

Group type: EXPERIMENTAL
Intervention: Sequential afatinib followed by osimertinib
Number of subjects: 0
Study: 31370866

Group type: EXPERIMENTAL
Intervention: Vitamin A deficiency in septic children
Number of subjects: 160
Study: 31370869

Group type: EXPERIMENTAL
Intervention: Hebrew version of the Western Ontario Shoulder Instability index (WOSI)
Number of subjects: 25
Study: 31370907

Group type: EXPERIMENTAL
Intervention: Ad libitum smoking
Number of subjects: 77

Group type: COMPARATOR
Intervention: Overnight smoking abstinence
Number of subjects: 77
Study: 31370954

Group type: EXPERIMENTAL
Intervention: RAS inhibitors
Number of subjects: 2785
Study: 31370978

Group type: EXPERIMENTAL
Intervention: Perception of fentanyl in heroin
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Past month injection drug use
Number of subjects: 239
Study: 31371173

Group type: EXPERIMENTAL
Intervention: 3 hours of procedural simulation training for difficult airway management
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Malleable intubation stylet
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Eschmann introducer
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Primary endpoint (frequency of use of devices)
Number of subjects: 60
Study: 31371191

Group type: EXPERIMENTAL
Intervention: Rivaroxaban treatment in patients with WRF
Number of subjects: 7509

Group type: COMPARATOR
Intervention: Rivaroxaban treatment in patients with SRF
Number of subjects: 7509
Study: 31371262

Group type: EXPERIMENTAL
Intervention: Cohort A (no lopinavir resistance) - second-line ART
Number of subjects: 545

Group type: EXPERIMENTAL
Intervention: Cohort B1 (best available NRTIs plus ritonavir-boosted darunavir plus raltegravir)
Number of subjects: 545

Group type: EXPERIMENTAL
Intervention: Cohort B2 (ritonavir-boosted darunavir plus raltegravir plus etravirine)
Number of subjects: 545

Group type: EXPERIMENTAL
Intervention: Cohort B3 (ritonavir-boosted darunavir, raltegravir, and either tenofovir plus emtricitabine or tenofovir plus lamivudine)
Number of subjects: 545

Group type: EXPERIMENTAL
Intervention: Cohort C (ritonavir-boosted darunavir plus raltegravir plus tenofovir-emtricitabine or tenofovir plus lamivudine)
Number of subjects: 545

Group type: EXPERIMENTAL
Intervention: Cohort D (best available NRTIs plus ritonavir-boosted darunavir plus raltegravir)
Number of subjects: 545

Group type: EXPERIMENTAL
Intervention: Overall (all cohorts)
Number of subjects: 545
Study: 31371339

Group type: EXPERIMENTAL
Intervention: Arthroscopic partial meniscectomy (APM)
Number of subjects: 194

Group type: COMPARATOR
Intervention: Exercise therapy
Number of subjects: 194

Group type: COMPARATOR
Intervention: Non-responders
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Responders
Number of subjects: 194
Study: 31371345

Group type: EXPERIMENTAL
Intervention: INCB054828 (pan-FGFR inhibitor)
Number of subjects: 1
Study: 31371350

Group type: EXPERIMENTAL
Intervention: Personalized OncoGenomics (POG) program
Number of subjects: 16
Study: 31371411

Group type: EXPERIMENTAL
Intervention: FDG-PET imaging
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard clinical assessment
Number of subjects: 0
Study: 31371414

Group type: EXPERIMENTAL
Intervention: High-dose methotrexate (HD-MTX) treatment, 5 g/m², during consolidation therapy.
Number of subjects: 1212
Study: 31371644

Group type: EXPERIMENTAL
Intervention: High-dose statin treatment
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Initial LDL-C levels
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Follow-up LDL-C levels
Number of subjects: 77
Study: 31372055

Group type: EXPERIMENTAL
Intervention: Erlotinib with gemcitabine/cisplatin or carboplatin
Number of subjects: 39
Study: 31372236

Group type: EXPERIMENTAL
Intervention: EQ-5D-5L
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: CAP-Sym 18 Questionnaire
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Late-Life Function and Disability Instrument (LLFDI)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Feasibility measures
Number of subjects: 44
Study: 31372961

Group type: EXPERIMENTAL
Intervention: Prefilled Syringe (PFS)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Autoinjector (AI)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Both PFS and AI
Number of subjects: 54
Study: 31373273

Group type: EXPERIMENTAL
Intervention: A-CHESS mobile health application with HCV intervention content including educational information, tailored messages, and a public discussion forum.
Number of subjects: 416

Group type: COMPARATOR
Intervention: Control group (details of the control intervention are not specified in the abstract).
Number of subjects: 416
Study: 31373712

Group type: EXPERIMENTAL
Intervention: Standardised mesalazine therapy
Number of subjects: 268
Study: 31374300

Group type: EXPERIMENTAL
Intervention: 300 mg dupilumab weekly for up to 76 weeks
Number of subjects: 1491
Study: 31374487

Group type: EXPERIMENTAL
Intervention: Lacosamide ≤8 mg/kg/day for Cohort 1 (aged 5-11 years); ≤12 mg/kg/day (≤600 mg/day) for age-based cohorts 2-5
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Lacosamide treatment
Number of subjects: 47
Study: 31374571

Group type: EXPERIMENTAL
Intervention: CT individuals
Number of subjects: 60
Study: 31375031

Group type: EXPERIMENTAL
Intervention: OneTouch Verio Reflect
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: OneTouch Ultra Plus Reflect
Number of subjects: 0
Study: 31375393

Group type: EXPERIMENTAL
Intervention: Decitabine treatment
Number of subjects: 116
Study: 31375469

Group type: EXPERIMENTAL
Intervention: PSMA PET tracer
Number of subjects: 50
Study: 31375510

Group type: EXPERIMENTAL
Intervention: Baseline cholesterol efflux capacity (CEC)
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: NODAT incidence
Number of subjects: 405
Study: 31375516

Group type: EXPERIMENTAL
Intervention: Detection of uniparental disomy (UPD)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: UPD on chromosome arm 13q
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: UPD on chromosome arm 6p
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: UPD on chromosome arm 11p
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Detection of UPDs of 13q and 11p
Number of subjects: 109
Study: 31375618

Group type: EXPERIMENTAL
Intervention: Prospective multicentre observational biobank, databank and imagebank of patients with AAA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Biomaterials collected include blood (including DNA and RNA), urine, and AAA tissue if open surgical repair is performed.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Imaging data obtained as part of clinical care stored in the imagebank.
Number of subjects: 0
Study: 31375837

Group type: EXPERIMENTAL
Intervention: Bezlotoxumab (10 mg/kg)
Number of subjects: 1554

Group type: EXPERIMENTAL
Intervention: Bezlotoxumab
Number of subjects: 1554

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1554
Study: 31376032

Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic cell transplantation (HCT)
Number of subjects: 145
Study: 31376090

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 14264

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 14264

Group type: EXPERIMENTAL
Intervention: Rivaroxaban and Warfarin
Number of subjects: 14264
Study: 31376493

Group type: EXPERIMENTAL
Intervention: Sustained virologic response (SVR)
Number of subjects: 4476

Group type: COMPARATOR
Intervention: No sustained virologic response (non-SVR)
Number of subjects: 4476
Study: 31376871

Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 584

Group type: EXPERIMENTAL
Intervention: Overweight
Number of subjects: 584

Group type: COMPARATOR
Intervention: Normal-weight
Number of subjects: 584
Study: 31376874

Group type: EXPERIMENTAL
Intervention: NT-proBNP
Number of subjects: 308
Study: 31377111

Group type: EXPERIMENTAL
Intervention: Enhanced recovery programme (ERP)
Number of subjects: 302